亲属活体供肾移植与尸体供肾移植的临床疗效比较

目的比较HLA配型和免疫抑制方案相同情况下亲属活体供肾移植与尸体供。肾移植的临床效果。方法对12例亲属活体供肾移植供、受者的临床资料进行回顾性分析，并与22例同期进行的、HLA配型情况相近的尸体供肾移植的临床资料进行对比，分析各组术后人／肾1年及3年存活率、1年内急性排斥反应发生率及3年内的。肾功能。结果12例供者均无手术并发症，术后肾功能正常，生活及工作未受明显影响。术后1年内的急性排斥反应发生率，亲属活体供。肾组和尸体供。肾组分别为16．7％和22．7％（P〈0．05）；人／肾1年和3年存活率，亲属活体供肾组分别为100％（12／12）／91．7％（11／12）和91．7％（11／12）／83．3％（10／12），尸体供。肾组分别为100％（22／22）／90．9％（20／22）和95．4％（21／22）／86．4％（19／22），两组比较，差异无统计学意义（P〉0．05）；3年内的。肾功能，亲属活体供肾移植组明显优于尸体供肾移植组（P〈0．05）。结论在HLA配型和免疫抑制方案相同的情况下，亲属活体供。肾移植的临床效果优于尸体供。肾移植。

Comparison of the clinical results between living related and cadaveric donor renal transplantation

Objective To compare the clinical results between living related and cadaveric donor renal transplantation in the same immunosuppressive regimen and HLA match. Methods Twelve cases of living related donor renal transplantation and 22 cases of cadaveric donor renal transplantation were analyzed retrospectively. The 1-, 3-year patient/graft survival rate, renal function and 1-year acute rejection rate were analyzed respectively.Results No renal function injury and surgical complications were found for living donors during the follow-up period. In living donor group and cadaveric donor group, 1-year acute rejection rate was 16.7 % and 22.7 % respectively (P< 0.05). 1-, 3-year patient/graft survival rate was 100 % (12/12) / 91.7 % (11/12) and 91.7 % (11/12)/ 83.3 % (10/12) in living donor group and 100 % (22/22)/ 90.9 % (20/22) and 95.4 % (21/22)/ 86.4 % (19/22) in cadaveric donor group respectively. No significant difference was found (P> 0.05). Renal function in living donor group was better than that in cadaveric donor group (P< 0.05) at the 3rd year.Conclusion By the same immunosuppressive regimen and HLA match, living donor group has a better clinical results than cadaveric donor group.